AR052659A1 - Derivados de purina agonistas del receptor de adenosina a2a - Google Patents
Derivados de purina agonistas del receptor de adenosina a2aInfo
- Publication number
- AR052659A1 AR052659A1 ARP060100129A ARP060100129A AR052659A1 AR 052659 A1 AR052659 A1 AR 052659A1 AR P060100129 A ARP060100129 A AR P060100129A AR P060100129 A ARP060100129 A AR P060100129A AR 052659 A1 AR052659 A1 AR 052659A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- optionally substituted
- group
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composiciones farmacéuticas que los contienen, usos terapéuticos y procesos de preparacion. Reivindicacion 1: Un compuesto de la formula (1) en forma libre o salina, en donde R1 designa un grupo heterocíclico de 3 a 10 miembros unido con N que contiene de 1 a 4 átomos de N del anillo y que contiene opcionalmente de 1 a 4 otros heteroátomos seleccionados del grupo que consiste en O y S, en donde ese grupo está opcionalmente sustituido con oxo, alcoxi C1-8, arilo C6-10, R4 o con alquilo C1- 8 opcionalmente sustituido con hidroxi; R2 es H o alquilo C1-8 opcionalmente sustituido con hidroxi o arilo C6-10; R3 es H, halo, alquenilo C2-8, alquinilo C2-8, o alcoxi C1-8-carbonilo, o R3 es amino opcionalmente sustituido con cicloalquilo C3-8 opcionalmente sustituido con amino, hidroxi, aralquiloxi C7-14, -SO2-arilo C6-10 o -NH-C(=O)-NH-R6, o R3 es amino sustituido con R4, - R4-aralquilo C7-14 o un grupo carbocíclico C5-15 opcionalmente sustituido con hidroxi, alquilo C1-8 o alcoxi C1-8- carbonilo, o R3 es aminocarbonilo opcionalmente sustituido con R5, o R3 es alquil C1-8-amino opcionalmente sustituido con hidroxi, R5, amino, di(alquil C1-8)amino, -NH-C(=O)-alquilo C1-8, -NH-SO2-alquilo C1-8, -NH-C(=O)-NH-R6, -NH-C(=O)-NH-C1-8- alquilo-R5, un grupo carbocíclico C5-15 o arilo C6-10 opcionalmente sustituido con ariloxi C6-10, o R3 es un grupo heterocíclico de 3 a 10 miembros unido con N que contiene de 1 a 4 átomos de N del anillo y que contiene opcionalmente de 1 a 4 otros heteroátomos seleccionados del grupo que consiste en O y S, en donde ese grupo está opcionalmente sustituido con amino, alquilo C1-8, alcoxi C1-8, alquil C1-8-amino, di(alquil C1-8) amino, R4, -R4-C(=O)-aralquiloxi C7-14, -NH-C(=O)-NH-R6, -NH-C(=O)- alcoxi C1-8, -NH-C(=O)-cicloalquilo C3-8, -NH-SO2-alquilo C1-8, -NH-C(=O)-NH-alquil C1-4-R4, -NH-C(=O)-NH-alquil C1-4-R4-arilo C6-10, -NH-C(=O)-NH-alquil C1-4-di(alquil C1-4)amino, -NH-C(=O)- NH-aril C6-10-R4, -NH-C(=O)-NH-aril C6-10-SO2NH2, -NH- C(=O)-NH-R6-aralquiloxi C7-14 o -NH-C(=O)-NH-aralquilo C7-14 opcionalmente sustituido con halo, hidroxilo, carboxi, -C(=NH)NH2 o alcoxi C1-4-carbonilo, o R3 es alquil C1-8-aminocarbonilo o cicloalquil C3-8-aminocarbonilo en cada caso opcionalmente sustituido con amino, alquil C1-8-amino, di(alquil C1-8)amino, -NH-C(=O)- di(alquil C1-8)amino, -NH-C(=O)-alquil C1-4-di(alquil C1-4)amino, -NH-C(=O)-alquil C1-4-R4-aralquilo C7-14, -NH-C(=O)-NH-R6, -NH- C(=O)-NH-alquilo C1-8, -NH-C(=O)-NH-alquil C1-8- amino, -NH-C(=O)-NH-di(alquil C1-4)amino, -NH-C(=O)-NH-aralquilo C7-14 o -NH- C(=O)-NH-R6-aralquiloxi C7-14; R4 y R5 son cada uno, de modo independiente entre sí un grupo heterocíclico de 5 a 12 miembros que al menos contiene un heteroátomo de anillo seleccionado del grupo que consiste en N, O y S; y R6 es un grupo heterocíclico de 5 o 6 miembros que al menos contiene un heteroátomo de anillo seleccionado del grupo que consiste en N, O y S, que está opcionalmente sustituido con un grupo heterocíclico de 5 o 6 miembros que al menos contiene un heteroátomo de anillo seleccionado del grupo que consiste en N, O y S.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0500785.1A GB0500785D0 (en) | 2005-01-14 | 2005-01-14 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052659A1 true AR052659A1 (es) | 2007-03-28 |
Family
ID=34224620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100129A AR052659A1 (es) | 2005-01-14 | 2006-01-12 | Derivados de purina agonistas del receptor de adenosina a2a |
Country Status (32)
Country | Link |
---|---|
US (1) | US8114877B2 (es) |
EP (1) | EP1841768B1 (es) |
JP (1) | JP2008526911A (es) |
KR (1) | KR20070093424A (es) |
CN (1) | CN101107249B (es) |
AR (1) | AR052659A1 (es) |
AT (1) | ATE414085T1 (es) |
AU (1) | AU2006205878B2 (es) |
BR (1) | BRPI0606324A2 (es) |
CA (1) | CA2593398A1 (es) |
CY (1) | CY1108752T1 (es) |
DE (1) | DE602006003628D1 (es) |
DK (1) | DK1841768T3 (es) |
ES (1) | ES2317483T3 (es) |
GB (1) | GB0500785D0 (es) |
GT (1) | GT200600013A (es) |
HK (1) | HK1112458A1 (es) |
HR (1) | HRP20090061T3 (es) |
IL (1) | IL184149A0 (es) |
MA (1) | MA29170B1 (es) |
MX (1) | MX2007008557A (es) |
MY (1) | MY141727A (es) |
NO (1) | NO20074050L (es) |
PE (1) | PE20060833A1 (es) |
PL (1) | PL1841768T3 (es) |
PT (1) | PT1841768E (es) |
RU (1) | RU2400483C2 (es) |
SI (1) | SI1841768T1 (es) |
TN (1) | TNSN07268A1 (es) |
TW (1) | TW200637863A (es) |
WO (1) | WO2006074925A1 (es) |
ZA (1) | ZA200704743B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0505219D0 (en) * | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8258141B2 (en) | 2006-04-21 | 2012-09-04 | Novartis Ag | Organic compounds |
GB0607951D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607954D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
KR20090087054A (ko) * | 2006-11-10 | 2009-08-14 | 노파르티스 아게 | 시클로펜텐 디올 모노아세테이트 유도체 |
WO2008116912A2 (en) * | 2007-03-28 | 2008-10-02 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
CA2717788A1 (en) | 2007-07-09 | 2009-01-15 | Eastern Virginia Medical School | Substituted nucleoside derivatives with antiviral and antimicrobial properties |
MX2010004234A (es) * | 2007-10-17 | 2010-04-30 | Novartis Ag | Derivados de purina como ligandos del receptor de adenosina a1. |
EP2408775B1 (en) * | 2009-03-20 | 2015-06-17 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
JP2012532140A (ja) | 2009-06-30 | 2012-12-13 | フォレスト・ラボラトリーズ・ホールディングス・リミテッド | A2ar作動薬としてのアルコキシ−カルボニル−アミノ−アルキニル−アデノシン化合物及びその誘導体 |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
WO2014001282A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
RU2018146946A (ru) * | 2016-06-08 | 2020-07-10 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения |
WO2018160824A1 (en) * | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
US4738954A (en) | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
US4873360A (en) | 1986-07-10 | 1989-10-10 | Board Of Governors Of Wayne State University | Process for the preparation of cyclopentanoids and novel intermediates produced thereby |
IL84414A0 (en) * | 1986-11-14 | 1988-04-29 | Ciba Geigy Ag | N9-cyclopentyl-substituted adenine derivatives |
US4954504A (en) | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
JP2586897B2 (ja) | 1987-03-09 | 1997-03-05 | 富士薬品工業株式会社 | 光学活性なシス−シクロペンテン−3,5−ジオ−ルモノエステルの製造法 |
DK0550631T3 (da) * | 1990-09-25 | 1997-01-20 | Rhone Poulenc Rorer Int | Forbindelser med blodtrykssænkende virkning og virkning mod iskæmi |
IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
US5688744A (en) * | 1995-11-03 | 1997-11-18 | Rohm And Haas Company | Antimicrobial compounds with quick speed of kill |
EA000884B1 (ru) | 1996-01-02 | 2000-06-26 | Рон-Пуленк Рорер Фармасьютикалз Инк. | Способ получения 2,4-дигидроксипиридина и 2,4-дигидрокси-3-нитропиридина |
US6376472B1 (en) | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
CA2289731A1 (en) | 1997-05-09 | 1998-11-12 | The United States Of America, Represented By The Secretary, Department O F Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
GB9813565D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813540D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
BR9911482A (pt) | 1998-06-23 | 2002-01-22 | Glaxo Group Ltd | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto |
BR9914526A (pt) | 1998-10-16 | 2001-07-03 | Pfizer | Derivados de adenina |
JP2002534430A (ja) | 1998-12-31 | 2002-10-15 | アベンティス・ファーマスーティカルズ・プロダクツ・インコーポレイテツド | N6−置換デアザアデノシン誘導体類の製造法 |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
GB9913932D0 (en) * | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
US6214807B1 (en) | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
GB0022695D0 (en) * | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
JP4012070B2 (ja) | 2001-01-16 | 2007-11-21 | カン−フィテ・バイオファーマ・リミテッド | ウイルスの複製を阻害するためのアデノシンa3受容体アゴニストの使用 |
GB2372741A (en) | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,8-Disubstituted adenosine derivatives and their different uses |
US20040162422A1 (en) | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
EP1258247A1 (en) | 2001-05-14 | 2002-11-20 | Aventis Pharma Deutschland GmbH | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes |
AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
AU2003234716A1 (en) | 2002-04-10 | 2003-10-27 | Joel M. Linden | Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases |
US7465715B2 (en) | 2003-12-29 | 2008-12-16 | Can-Fite Biopharma, Ltd. | Method for treatment of multiple sclerosis |
CA2557285A1 (en) | 2004-03-05 | 2005-09-15 | Cambridge Biotechnology Limited | Adenosine receptor agonists |
WO2005107463A1 (en) | 2004-05-03 | 2005-11-17 | University Of Virginia Patent Foundation | Agonists of a2a adenosine receptors for treatment of diabetic nephropathy |
AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
EP1778239B1 (en) | 2004-07-28 | 2013-08-21 | Can-Fite Biopharma Ltd. | Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome |
US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
US7825126B2 (en) | 2004-09-09 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Purine derivatives as A3 and A1 adenosine receptor agonists |
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
US20080051364A1 (en) | 2004-11-08 | 2008-02-28 | Pninna Fishman | Therapeutic Treatment of Accelerated Bone Resorption |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
WO2006084281A1 (en) | 2005-02-04 | 2006-08-10 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
GB0505219D0 (en) | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
ATE540673T1 (de) | 2005-11-30 | 2012-01-15 | Can Fite Biopharma Ltd | Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis |
KR101383228B1 (ko) | 2006-01-26 | 2014-04-09 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 | A3 아데노신 수용체 알로스테릭 조절제 |
WO2007092213A2 (en) | 2006-02-02 | 2007-08-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzyme |
WO2007092936A2 (en) | 2006-02-08 | 2007-08-16 | University Of Virginia Patent Foundation | Method to treat gastric lesions |
GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607951D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607948D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607944D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607954D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607953D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8258141B2 (en) * | 2006-04-21 | 2012-09-04 | Novartis Ag | Organic compounds |
EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
KR20090087054A (ko) | 2006-11-10 | 2009-08-14 | 노파르티스 아게 | 시클로펜텐 디올 모노아세테이트 유도체 |
US20080312160A1 (en) | 2007-04-09 | 2008-12-18 | Guerrant Richard L | Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist |
US20080262001A1 (en) | 2007-04-23 | 2008-10-23 | Adenosine Therapeutics, Llc | Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection |
AU2008270735C1 (en) | 2007-06-29 | 2014-03-06 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily |
US20090181934A1 (en) | 2007-10-17 | 2009-07-16 | Novartis Ag | Organic Compounds |
MX2010004234A (es) * | 2007-10-17 | 2010-04-30 | Novartis Ag | Derivados de purina como ligandos del receptor de adenosina a1. |
WO2009061516A1 (en) | 2007-11-08 | 2009-05-14 | New York University School Of Medicine | Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening |
BRPI0907248A2 (pt) | 2008-01-09 | 2019-02-26 | Pgxhealth, Llc | tratamento intratecal de dor neuropática com agonistas a2ar |
-
2005
- 2005-01-14 GB GBGB0500785.1A patent/GB0500785D0/en not_active Ceased
-
2006
- 2006-01-06 MY MYPI20060048A patent/MY141727A/en unknown
- 2006-01-11 GT GT200600013A patent/GT200600013A/es unknown
- 2006-01-12 PL PL06700452T patent/PL1841768T3/pl unknown
- 2006-01-12 CN CN2006800024512A patent/CN101107249B/zh not_active Expired - Fee Related
- 2006-01-12 CA CA002593398A patent/CA2593398A1/en not_active Abandoned
- 2006-01-12 PT PT06700452T patent/PT1841768E/pt unknown
- 2006-01-12 WO PCT/EP2006/000217 patent/WO2006074925A1/en active Application Filing
- 2006-01-12 EP EP06700452A patent/EP1841768B1/en active Active
- 2006-01-12 AR ARP060100129A patent/AR052659A1/es not_active Application Discontinuation
- 2006-01-12 JP JP2007550752A patent/JP2008526911A/ja active Pending
- 2006-01-12 ES ES06700452T patent/ES2317483T3/es active Active
- 2006-01-12 AU AU2006205878A patent/AU2006205878B2/en not_active Ceased
- 2006-01-12 RU RU2007130802/04A patent/RU2400483C2/ru not_active IP Right Cessation
- 2006-01-12 DE DE602006003628T patent/DE602006003628D1/de active Active
- 2006-01-12 KR KR1020077016098A patent/KR20070093424A/ko not_active Application Discontinuation
- 2006-01-12 AT AT06700452T patent/ATE414085T1/de active
- 2006-01-12 US US11/722,835 patent/US8114877B2/en not_active Expired - Fee Related
- 2006-01-12 DK DK06700452T patent/DK1841768T3/da active
- 2006-01-12 BR BRPI0606324-1A patent/BRPI0606324A2/pt not_active IP Right Cessation
- 2006-01-12 SI SI200630194T patent/SI1841768T1/sl unknown
- 2006-01-12 MX MX2007008557A patent/MX2007008557A/es active IP Right Grant
- 2006-01-13 TW TW095101304A patent/TW200637863A/zh unknown
- 2006-01-13 PE PE2006000062A patent/PE20060833A1/es not_active Application Discontinuation
-
2007
- 2007-06-20 ZA ZA200704743A patent/ZA200704743B/xx unknown
- 2007-06-21 IL IL184149A patent/IL184149A0/en unknown
- 2007-07-13 TN TNP2007000268A patent/TNSN07268A1/en unknown
- 2007-07-26 MA MA30103A patent/MA29170B1/fr unknown
- 2007-08-06 NO NO20074050A patent/NO20074050L/no not_active Application Discontinuation
-
2008
- 2008-02-04 HK HK08101328.3A patent/HK1112458A1/xx not_active IP Right Cessation
-
2009
- 2009-02-03 HR HR20090061T patent/HRP20090061T3/xx unknown
- 2009-02-05 CY CY20091100134T patent/CY1108752T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052659A1 (es) | Derivados de purina agonistas del receptor de adenosina a2a | |
AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
AR056875A1 (es) | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos | |
AR107154A1 (es) | Estimuladores de guanilato ciclasa soluble | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
ES2067456T3 (es) | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composicion farmaceutica que los comprende. | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
ECSP12011857A (es) | Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso | |
AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
PE20000048A1 (es) | Prodrogas de inhibidores de aspartil proteasa | |
AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
AR081637A1 (es) | Derivados del acido c-3-betulinico modificados inhibidores de la maduracion del vih, composiciones farmaceuticas que los contienen e intermediarios de sintesis | |
BR112014023384A8 (pt) | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
ES2630079T3 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
AR035651A1 (es) | Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion | |
AR082498A1 (es) | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide | |
AR046170A1 (es) | Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b | |
AR118983A1 (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
AR053345A1 (es) | Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa | |
AR012436A1 (es) | Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion. | |
AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |